Loading
The oncogeneticist who found most of the common genetic variants that raise a man's risk of prostate cancer, and whose work is the reason the UK's first prostate screening programme is defined by a gene rather than by an age.
Rosalind Eeles is Professor of Oncogenetics at the Institute of Cancer Research and a consultant in clinical oncology and cancer genetics at The Royal Marsden. She founded the PRACTICAL consortium, the international collaboration that carried out the genome-wide association studies behind the majority of known common prostate cancer risk variants, and she leads the targeted screening studies that follow from them: IMPACT, which screens men with BRCA1 and BRCA2 variants, and BARCODE, which tests whether a polygenic risk score can be used to decide who is invited.
The UK National Screening Committee's March 2026 recommendation is the first practical outcome of that line of work in NHS policy: biennial PSA testing for men aged 45 to 61 with a pathogenic BRCA2 variant and a relevant family history. The committee was explicit that the evidence for a polygenic route is not yet there, and that TRANSFORM is the trial that will supply it.
Shares TRANSFORM, Localised prostate cancer, high and very high risk, Prostate cancer and the tags prostate, uk.
Shares TRANSFORM, Prostate cancer and the tags prostate, uk.
Shares Johann de Bono, The Institute of Cancer Research, The Royal Marsden.
Shares The Institute of Cancer Research, The Royal Marsden and the tag uk.
Shares The Institute of Cancer Research, The Royal Marsden and the tag uk.
Shares Prostate cancer and the tags prostate, uk.
Shares Prostate cancer and the tags prostate, uk.
Shares Prostate cancer and the tags prostate, uk.